924 results on '"Foster, Graham R."'
Search Results
2. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set
3. HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol
4. Adeno-associated viruses for gene therapy – clinical implications and liver-related complications, a guide for hepatologists
5. The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia
6. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
7. Hepatitis C
8. Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists
9. Viral hepatitis elimination: Towards a hepatitis-free world
10. Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost
11. Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan: Findings from two sero‐surveys in 2007 and 2019.
12. Risk factors for hepatocellular carcinoma associated with hepatitis C genotype 3 infection: A systematic review
13. Hepatitis after gene therapy, what are the possible causes?
14. The complex, confusing and poorly understood immune responses to AAV‐mediated gene transfer in haemophilia—Is more or less immunosuppression required?
15. The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation
16. Hepatosplenic schistosomiasis in Zambian adults is characterized by increased liver stiffness: A nested case-control study
17. An informatics consult approach for generating clinical evidence for treatment decisions
18. Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir
19. Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies
20. Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial
21. Joint statement in support of hepatitis C human challenge studies
22. Adeno-associated viruses for gene therapy – clinical implications and liver related complications, a guide for hepatologists
23. A large-scale, multi-centre, prospective observational study to treat hepatitis C in Pakistan and assess resistance to antiviral drugs (HepFREEPak): study protocol
24. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis
25. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale‐up in the age of direct‐acting antivirals
26. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
27. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials
28. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials
29. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
30. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
31. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse
32. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis
33. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation
34. Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?
35. The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis
36. Liver-related aspects of gene therapy for haemophilia: Call to action for collaboration between haematologists and hepatologists
37. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
38. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials
39. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials
40. Joint statement in support of hepatitis C human challenge studies
41. Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B
42. Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention
43. Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B
44. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
45. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
46. Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study
47. Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified
48. Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?
49. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
50. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.